PracticeUpdate Conference Series ASH 2018

First page Table of contents Next page Last page

Shorter Course of CHOP + Rituximab Noninferior to Standard of Care in Younger Patients With DLBCL	4
Expedited Genetic Screening Feasible for Detecting Subtypes of Acute Myeloid Leukemia	5
Combining CAR T-Cell Therapy With PD-1 Checkpoint Inhibitors Could Improve Response Persistence	6
L-Glutamine Benefits Consistent Regardless of History of Sickle Cell Disease Crises	7
Microbiome Injury Prior to Hematopoietic Stem Cell Transplantation Predicts Survival	8
Hydroxyurea a Feasible Sickle Cell Therapy in Sub-Saharan Africa	10
First Transplant Following CAR T-Cell Therapy Boosts Leukemia-Free Survival in ALL	11
Doctors Underestimate the Impact of Fatigue Related to Immune Thrombocytopenia	12
Smoking Linked With Poorer Outcomes In Newly Diagnosed ALL Treated With TKIs	13
Older Patients With CLL See Better Outcomes With Ibrutinib Than Chemoimmunotherapy	14
Luspatercept Reduces Need for Blood Transfusions Among Patients With Beta Thalassemia	15
Direct Oral Anticoagulants Safely Reduce Clotting Risk In Outpatient Cancer Setting	16
Ibrutinib-Based Therapy Beats Standard of Care as First-Line in Young Patients With CLL	16
Daratumumab Improves Outcomes in Fragile Patients With Multiple Myeloma	18
Emapalumab Safe and Effective in Pediatric Patients With Primary HLH	19
Tisagenlecleucel Effectively Treats ALL in Update of ELIANA Trial	20

Made with FlippingBook HTML5